Signatera™ for Uterine Cancers

Identify which uterine cancer patients are most likely to recur post-surgery with superior sensitivity over standard methods.

Monitor IO treatment response in real-time to accurately distinguish clinical progression from pseudoprogression.

Speak with an expert

Powering clinical decisions in uterine cancer

Understand risk

7.6x

more likely to experience recurrence if you are ctDNA positive within the first 3.5 months.¹

Detect recurrence earlier

3.1 mo

median lead time – Signatera™ identified 100% of recurrences before imaging.¹

Predict treatment response

100%

of patients who were serially Signatera™ negative remained recurrence-free, regardless of p53 and MMR status.^1,2

Identify those at greatest risk of recurrence

Signatera™ positivity was highly prognostic for reduced RFS¹

Read publication

SGN_WB_MD_Endometrial_20260508_NAT-8023515_TextImage_0

SGN_WB_MD_Endometrial_20260508_NAT-8023515_TextImage (2)

Signatera™ identified 100% of recurrences before imaging²

Positivity at the first time point and longitudinally experienced inferior RFS.
None of the serially negative patients experienced recurrence.

Signatera™ was the only significant risk factor for recurrence²

SGN_WB_MD_Endometrial_20260526_NAT-8023515_TextImage2

Tailor uterine cancer treatment with Natera’s portfolio of genomic tests

Altera™

Comprehensive genomic profiling for clinically relevant biomarkers that may help guide treatment selection (including MSI, BRCA 1/2, HR genes, MMR genes, TMB, BRAF, RET, and NTRK), with no additional timor sample needed.

Empower™

Germline genetic test for commonly screened genes in gynecologic cancers )eg BRCA 1/2, MMR genes) to inform therapeutic decisions.

Is Signatera™ for Uterine cancer right for your patients?

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

¹Ketch, et al. Utilizing Circulating Tumor DNA (ctDNA)-based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine Cancer. JCO Precision Oncology. 2025;9:e2500286.

²Recio F, Scalise CB, Loar P, Lumish M, Berman T, Peddada A, et al. Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies. Gynecologic Oncology. 2024;182:63-69.

³Bratman SV, Yang SC, Iafolla MA, Liu Z, Hansen AR, Bedard PL, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nature Cancer. 2020;1(9):873-881.